FDAnews
www.fdanews.com/articles/75677-cel-sci-receives-clinical-trial-go-ahead-for-cancer-drug

CEL-SCI RECEIVES CLINICAL TRIAL GO-AHEAD FOR CANCER DRUG

August 23, 2005

CEL-SCI announced that it has begun a Phase III clinical trial in head and neck cancer patients using its immunotherapy drug Multikine.

Approximately 500 patients will be enrolled worldwide in the Phase III trial. The protocol is designed to develop conclusive evidence of the efficacy of Multikine in the treatment of advanced primary squamous cell carcinoma of the oral cavity (head and neck cancer).

The trial will test the hypothesis that Multikine treatment administered prior to the current standard therapy for head and neck cancer patients (surgical resection of the tumor and involved lymph nodes followed by radiotherapy or radiotherapy and concurrent chemotherapy) will enhance the local/regional control of the disease, reduce the rate of disease progression and extend the time of progression free survival in patients with advanced oral squamous cell carcinoma.